These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30223097)

  • 1. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
    Nizam E; Erin N
    Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
    Nizam E; Köksoy S; Erin N
    Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
    Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG
    Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer.
    Zhou Y; Zhao L; Xiong T; Chen X; Zhang Y; Yu M; Yang J; Yao Z
    Breast Cancer Res Treat; 2013 Jul; 140(1):49-61. PubMed ID: 23807418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
    Erin N; Nizam E; Tanrıöver G; Köksoy S
    Breast Cancer Res Treat; 2015 Feb; 150(1):57-69. PubMed ID: 25682075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurokinin 1 and 2 receptors are involved in PGE
    Zhuang J; Gao X; Zhao L; Wei W; Xu F
    Respir Physiol Neurobiol; 2022 Dec; 306():103952. PubMed ID: 35905863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of PKC-delta on substance P-induced chemokine synthesis in pancreatic acinar cells.
    Ramnath RD; Sun J; Adhikari S; Zhi L; Bhatia M
    Am J Physiol Cell Physiol; 2008 Mar; 294(3):C683-92. PubMed ID: 18160487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intravenous administration of neurokinin receptor subtype-selective agonists on gonadotropin-releasing hormone pulse generator activity and luteinizing hormone secretion in goats.
    Yamamura T; Wakabayashi Y; Ohkura S; Navarro VM; Okamura H
    J Reprod Dev; 2015; 61(1):20-9. PubMed ID: 25345909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
    Herpfer I; Lieb K
    CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK1R/5-HT1AR interaction is related to the regulation of melanogenesis.
    Wu H; Zhao Y; Huang Q; Cai M; Pan Q; Fu M; An X; Xia Z; Liu M; Jin Y; He L; Shang J
    FASEB J; 2018 Jun; 32(6):3193-3214. PubMed ID: 29430989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance P enhances the local activation of NK
    Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W
    BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
    Tauer U; Zhao Y; Hunt SP; Culman J
    Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
    Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
    Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
    Akazawa T; Kwatra SG; Goldsmith LE; Richardson MD; Cox EA; Sampson JH; Kwatra MM
    J Neurochem; 2009 May; 109(4):1079-86. PubMed ID: 19519779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering specificity and cross-reactivity in tachykinin NK1 and NK2 receptors.
    Madsen JJ; Petersen JE; Christensen DP; Hansen JB; Schwartz TW; Frimurer TM; Olsen OH
    J Biol Chem; 2023 Dec; 299(12):105438. PubMed ID: 37944618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
    Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L
    Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R).
    Chernova I; Lai JP; Li H; Schwartz L; Tuluc F; Korchak HM; Douglas SD; Kilpatrick LE
    J Leukoc Biol; 2009 Jan; 85(1):154-64. PubMed ID: 18835883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells.
    Gallicchio M; Rosa AC; Benetti E; Collino M; Dianzani C; Fantozzi R
    Br J Pharmacol; 2006 Mar; 147(6):681-9. PubMed ID: 16432508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
    Munoz M; Recio S; Rosso M; Redondo M; Covenas R
    J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.